REG - Futura Medical PLC - Directors' / PDMR dealing

Futura MedicalAnnouncement

08/12/2025 12:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251208:nRSH6832Ka&default-theme=true

RNS Number : 6832K  Futura Medical PLC  08 December 2025

8 December 2025

Futura Medical plc

("Futura" or the "Company")

Directors' / PDMR Dealing

Futura Medical plc (AIM: FUM), the consumer healthcare company behind
Eroxon(®), that specialises in the development and global commercialisation
of innovative and clinically proven sexual health products, confirms that the
following Directors and persons closely associated subscribed for an aggregate
of 6,000,000 Ordinary Shares in the Company pursuant to the Fundraise
announced on 13 November 2025.

 

Details are as below:

 

 Director         Number of New Shares  Issue Price per Ordinary Share  Total number of Ordinary Shares held following Admission      Percentage of Enlarged Share Capital
 Alex Duggan*     5,000,000             1 pence                         5,000,000                                                     0.86%
 Angela Hildreth  500,000               1 pence                         642,857                                                       0.11%
 Ken James        500,000               1 pence                         799,501                                                       0.14%

 

 

Further disclosures are contained in the tables below.

 

·      Alex Duggan's shares were purchased by a wholly owned entity,
Appia Healthcare Limited.

 

 

Capitalised terms not defined in this announced have the meanings given to
them in the Fundraise Announcement dated 13 November 2025.

 

ENDS

 

Contacts:

 Futura Medical plc                 Alex Duggan                                                investor.relations@futuramedical.com

                                                          (mailto:Investor.relations@futuramedical.com)
                                    Chief Executive Officer

                                                          +44 (0)1483 685 670
                                    Angela Hildreth

                                                          www.futuramedical.com (http://www.futuramedical.com/)
                                    Finance Director and COO

 Panmure Liberum                    Emma Earl, Will Goode, Mark Rogers (Corporate Finance)     +44 (0)20 3100 2000

 Nominated Adviser                  Rupert Dearden (Corporate Broking)

 and Broker

 Turner Pope Investments (TPI) Ltd  Guy McDougall / Andrew Thacker                             +44 (0) 20 3657 0050

 Broker

 Alma Strategic Communications      Rebecca Sanders-Hewett                                     +44 (0)20 3405 0205

                                    Sam Modlin                                                 futura@almastrategic.com (mailto:futura@almastrategic.com)

                                    Emma Thompson

 

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and development products WSD4000
and Eroxon(®) Intense. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. Erectile Dysfunction
("ED") impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. Around 60% of women experience at least one
symptom of sexual dysfunction, and only one in four women seek professional
help, and remain chronically underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection in ten minutes, addresses significant unmet needs in the ED market.
Eroxon(®) has been nominated for a number of healthcare industry awards and
has won two to-date.

 

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

 

WSD4000 is a topical treatment designed for the symptoms of impaired sexual
response and function in women. There is currently no regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal and lubrication.

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Alex Duggan
 2   Reason for the notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Futura Medical plc
 b)  LEI                                                          21380053QLT46UNV2303
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument   Ordinary shares at 0.2p each

     Identification code                                           GB0033278473
 b)  Nature of the transaction                                    Subscription for ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            1.  1p        5,000,000

 
 d)  Aggregated information                                       1. 5,000,000

     -         Aggregated volume

     -         Price

                                                                  1. £50,000

 e)  Date of the transaction                                      4 December 2025
 f)  Place of the transaction                                     1. Outside a trading venue

 

d)

Aggregated information

-         Aggregated volume

-         Price

1. 5,000,000

 

 

1. £50,000

 

e)

Date of the transaction

4 December 2025

f)

Place of the transaction

1. Outside a trading venue

 

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Ken James
 2   Reason for the notification
 a)  Position/status                                              Executive Director

and Head of R&D
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Futura Medical plc
 b)  LEI                                                          21380053QLT46UNV2303
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares at 0.2p each

     Identification code                                           GB0033278473
 b)  Nature of the transaction                                    Subscription for ordinary shares

 c)  Price(s) and volume(s)                                           Price(s)  Volume(s)

                                                            1.  1p        500,000

 
 d)  Aggregated information                                       1. 500,000

     -         Aggregated volume

     -         Price

                                                                  1. £5,000

 e)  Date of the transaction                                      4 December 2025
 f)  Place of the transaction                                     1. Outside a trading venue

 

d)

Aggregated information

-         Aggregated volume

-         Price

1. 500,000

 

 

1. £5,000

 

e)

Date of the transaction

4 December 2025

f)

Place of the transaction

1. Outside a trading venue

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Angela Hildreth
 2   Reason for the notification
 a)  Position/status                                              FD/COO
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Futura Medical plc
 b)  LEI                                                          21380053QLT46UNV2303
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares at 0.2p each

     Identification code                                           GB0033278473
 b)  Nature of the transaction                                    Subscription for ordinary shares

 c)  Price(s) and volume(s)                                           Price(s)  Volume(s)

                                                            1.  1p        500,000

 
 d)  Aggregated information                                       1. 500,000

     -         Aggregated volume

     -         Price

                                                                  1. £5,000

 e)  Date of the transaction                                      4 December 2025
 f)  Place of the transaction                                     1. Outside a trading venue

 

d)

Aggregated information

-         Aggregated volume

-         Price

1. 500,000

 

 

1. £5,000

 

e)

Date of the transaction

4 December 2025

f)

Place of the transaction

1. Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFSMFEAEISEFE



            Copyright 2019 Regulatory News Service, all rights reserved